Press Releases
IXICO releases financial results for the year ended 30 Sept 2021
IXICO plc (AIM: IXI) announces its results for the year ended 30 September 2021, delivering a year of significant growth in profitability despite notable headwinds to trading. HighlightsFinancial EBITDA* of £1. 7 million; 34% increase on prior year (2020: £1.
Read more
Phase III demyelinating disorder contract award with largest Pharma client worth >£1.0m
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by its largest pharma client to provide neuroimaging services for a new Phase III clinical trial focused on a demyelinating disorder.
Read more
Contract Update
IXICO plc, the data analytics company delivering insights in neuroscience, announces that it has been notified by a client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data. The client will therefore end its trial while it undertakes additional preclinical studies.
Read more
Trading Update for year ended 30 September 2021
£9. 2 million revenues outperform market expectations EBITDA profitability expected to be materially ahead of market expectations Strong £18. 8 million order book and £6. 7 million cash position. IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces a trading update for the year ended 30 September 2021.
Read more
First contract award from new Imaging Master Vendor Agreement with top 5 global CRO
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a new contract with a value of more than >$750k over 2 years for advanced neuroimaging solutions by a top 5 global Clinical Research Organization ("CRO") to support its sponsor's Phase II Alzheimer's disease clinical trial.
Read more
Phase II Huntington's disease contract award with new client worth >$500K
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new US biopharmaceutical client to support its Phase II Huntington's disease (HD) clinical trial. HD is a rare condition of the nervous system that impacts the way people think, behave, and move.
Read more
Phase I Multiple System Atrophy contract award worth >$500k
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been awarded a contract by a new biopharmaceutical client to support its Phase I multiple system atrophy clinical trial.
Read more
Trading Update
Expected FY21 financial performance of £8. 7m revenues and c. £1. 2m EBITDA thereby maintaining strong EBITDA margin performance. IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces a trading update, confirming that, despite a challenging business environment, it expects to deliver £8.
Read more1-8 of 55 results